Literature DB >> 31120638

Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.

Srilakshmi Bathini1, Noa G Holtzman1, Rima Koka2, Zeba Singh2, Emily Wilding2, Ying Zou2, Kathleen Ruehle1, Mehmet H Kocoglu1, Ashraf Badros1, Nancy Hardy1, Jean Yared1, Aaron P Rapoport1, Magali Fontaine2, Ashkan Emadi1, Firas El Chaer1, Saurabh Dahiya1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31120638     DOI： 10.1002/ajh.25515

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

Review 1.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483

2.  Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation.

Authors:  Yang Gao; Fei Gao; Jimin Shi; Huarui Fu; He Huang; Yanmin Zhao
Journal:  J Zhejiang Univ Sci B       Date:  2021-08-15       Impact factor: 3.066

3.  Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature.

Authors:  Lina Driouk; Robert Schmitt; Anke Peters; Sabine Heine; Hermann Josef Girschick; Brigitte Strahm; Charlotte M Niemeyer; Carsten Speckmann
Journal:  Mol Cell Pediatr       Date:  2021-04-29

Review 4.  Immunotherapy for Refractory Autoimmune Encephalitis.

Authors:  Jiawei Yang; Xueyan Liu
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.